scispace - formally typeset
J

Jay P. Morgenstern

Researcher at Millennium Pharmaceuticals

Publications -  8
Citations -  2974

Jay P. Morgenstern is an academic researcher from Millennium Pharmaceuticals. The author has contributed to research in topics: SH2 domain & Proto-oncogene tyrosine-protein kinase Src. The author has an hindex of 7, co-authored 8 publications receiving 2884 citations.

Papers
More filters
Journal ArticleDOI

Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice.

TL;DR: It is predicted that the long intrACEllular domain form of OB-R is crucial for initiating intracellular signal transduction, and as a corollary, the inability to produce this form ofOB-R leads to the severe obese phenotype found in db/db mice.
Journal ArticleDOI

Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor

TL;DR: The crystal structure of the tandem SH2 domains of human ZAP-70 in complex with a peptide derived from the ζ-subunit of the T-cell receptor reveals an unanticipated interaction between the two domains that constitutes one of the two critical phosphotyrosine binding sites.
Journal ArticleDOI

Constitutive and impaired signaling of leptin receptors containing the Gln → Pro extracellular domain fatty mutation

TL;DR: In this article, a single amino acid substitution at position 269 (Gln → Pro) in the OB-R extracellular domain that results in the obese phenotype of the fatty rat was analyzed.
Journal ArticleDOI

Tyrosine Phosphorylation of Tub and Its Association with Src Homology 2 Domain-containing Proteins Implicate Tub in Intracellular Signaling by Insulin

TL;DR: It is demonstrated that in CHO-IR cells, transfected Tub is phosphorylated on tyrosine in response to insulin and insulin-like growth factor-1 and that in PC12 cells, insulin but not EGF induced tyosine phosphorylation of endogenous Tub.
Journal ArticleDOI

Genome-Wide siRNA Screen for Modulators of Cell Death Induced by Proteasome Inhibitor Bortezomib

TL;DR: The results suggest that proteasome inhibition promotes cell death primarily by dysregulating Myc and polyamines, interfering with protein translation, and disrupting essential DNA damage repair pathways, leading to programmed cell death.